29 Oct 2026

Poland’s Council of Ministers approved a bill on 27 October to amend the Reimbursement Act, advancing a package of nearly 200 changes to pharmaceutical pricing, coverage and administration. The measure moves the draft reform previously reported by LiSAH in March into the parliamentary stage, while its provisions remain subject to legislative approval.

The Ministry of Health (Ministerstwo Zdrowia, MZ) says the bill addresses practical difficulties arising from the 2023 reimbursement reforms. It would simplify applications, strengthen electronic administration and allow preparations for new drug programmes to begin before a positive reimbursement decision takes effect, supporting access from the first day of coverage.

New provisions would introduce a definition of orphan medicines for multicriteria assessment, allowing clinical and other factors to be considered where small patient populations limit the evidence base. The Minister could also invite manufacturers to submit reimbursement applications in areas of unmet need.

The bill further links reimbursement to domestic pharmaceutical manufacturing. The Ministry describes patient co-payment reductions of up to 30% for qualifying Polish-made medicines and a national list of critical medicines. The eligibility of the manufacturing incentives depends on where both the medicine and its active substance are produced.

Government approval is a legislative milestone for proposals already under development. Final wording and commencement dates will determine their effect on application requirements, evidence assessment, patient charges and domestic-production incentives.

Source: Ministry of Health, Poland
Link: Sprawniejszy system refundacyjny i wzmocnione bezpieczeństwo lekowe – Rada Ministrów przyjęła projekt zmian w ustawie refundacyjnej (A more efficient reimbursement system and stronger medicines security – the Council of Ministers adopts the draft amendment to the Reimbursement Act)
Date: 27 October 2026